EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Why are we doing this alone? A collaborative framework for LDT development and validation

James E Kirby iD, Ramy Arnaout iD

Journal of Clinical Microbiology · 08.04.2026 · 64 (4)

DOI: 10.1128/jcm.01867-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Microbiology, erschienen am 08.04.2026. Verfasst von James E Kirby und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Molecular Diagnostic Techniques, Communicable Diseases, Diagnostic Tests, Routine. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Laboratory-developed tests (LDTs) play a critical role in meeting unmet diagnostic needs, particularly for rare infections and high-acuity or immunocompromised patient populations. However, current US regulatory and reimbursement frameworks have constrained innovation and delayed implementation of many essential laboratory diagnostic tests. Here, we propose a pragmatic, collaborative model focusing on infectious disease molecular diagnostics that maintains analytical rigor while allowing clinical validity to be supported by evidence from the medical literature and clinical judgment. To address the resource constraints faced by hospital laboratories, we envision a voluntary, national repository where laboratories and manufacturers contribute standardized analytical and, where appropriate, clinical validation data for both newly developed and modified Food and Drug Administration (FDA)-cleared assays. Data elements such as accuracy, limit of detection, analytical measurement range, analytical specificity, and inclusivity compared with reference determinations would be aggregated within groups representing technically identical assays, enabling cumulative validation and shared use of high-quality evidence. By leveraging these shared data sets, hospital laboratories could implement LDTs in-house with minimal redundant validation, enabling broader access to testing near the point of patient care and faster turnaround times. Manufacturers could use the same data to support applications for expanded intended use of existing FDA-cleared and -approved tests. This framework would strengthen hospital laboratory diagnostic capacity, accelerate test implementation, and improve patient outcomes and healthcare system efficiency.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Molecular Diagnostic TechniquesCommunicable DiseasesDiagnostic Tests, RoutineHumansUnited StatesSensitivity and SpecificityUnited States Food and Drug AdministrationReproducibility of Results

Stichwörter der Autor:innen

LDTanalytical validationclinical microbiologylaboratory developed testmolecular diagnosticsregulationvalidationverification

Autor:innen und Institutionen

  • Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: James E Kirby, Ramy Arnaout

Zitieren

APA

Kirby, J. E., & Arnaout, R. (2026). Why are we doing this alone? A collaborative framework for LDT development and validation. Journal of Clinical Microbiology, 64(4). https://doi.org/10.1128/jcm.01867-25

Vancouver

Kirby JE, Arnaout R. Why are we doing this alone? A collaborative framework for LDT development and validation. Journal of Clinical Microbiology. 2026;64(4). doi:10.1128/jcm.01867-25

BibTeX
@article{Kirby2026,
  author = {Kirby, James E and Arnaout, Ramy},
  title = {Why are we doing this alone? A collaborative framework for LDT development and validation},
  journal = {Journal of Clinical Microbiology},
  year = {2026},
  volume = {64},
  number = {4},
  doi = {10.1128/jcm.01867-25}
}
Kostenlos starten →